Bayer’s BlueRock now plans to bring Parkinson’s cell therapy straight to Phase 3 trialnews2025-01-13T07:30:48+00:00January 13th, 2025|Endpoints News|
Pfizer touts bladder cancer results as first advancement for some patients ‘in decades’news2025-01-10T19:17:13+00:00January 10th, 2025|Endpoints News|
Dyne details pivotal plans for myotonic dystrophy RNA drug, though data blip worries some investorsnews2025-01-10T16:41:00+00:00January 10th, 2025|Endpoints News|
Repare pauses late-stage plans, reshuffles pipeline in effort to cut costsnews2025-01-10T11:51:11+00:00January 10th, 2025|Endpoints News|
Marea reports early Phase 2 data for cholesterol-lowering drug it licensed from Novartisnews2025-01-10T11:09:49+00:00January 10th, 2025|Endpoints News|
IGM Biosciences’ autoimmune pivot lasts three months after interim data disappointnews2025-01-09T20:26:03+00:00January 9th, 2025|Endpoints News|
Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatmentnews2025-01-09T19:58:36+00:00January 9th, 2025|Endpoints News|
Tenpoint reveals positive Phase 3 data for vision drugnews2025-01-09T18:59:34+00:00January 9th, 2025|Endpoints News|
Aiolos team reunites with $411M for new biotech with obesity drugs from Chinanews2025-01-09T07:00:33+00:00January 9th, 2025|Endpoints News|
MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatmentnews2025-01-08T21:20:26+00:00January 8th, 2025|Endpoints News|
